AMEX:AGE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has AgeX Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AGE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

47.0%

AGE

0.5%

US Biotechs

3.0%

US Market


1 Year Return

-56.9%

AGE

27.3%

US Biotechs

9.9%

US Market

Return vs Industry: AGE underperformed the US Biotechs industry which returned 27.3% over the past year.

Return vs Market: AGE underperformed the US Market which returned 9.9% over the past year.


Shareholder returns

AGEIndustryMarket
7 Day47.0%0.5%3.0%
30 Day39.5%9.2%8.2%
90 Day1.8%12.8%0.4%
1 Year-56.9%-56.9%28.6%27.3%12.4%9.9%
3 Yearn/a34.7%30.2%31.0%22.3%
5 Yearn/a-1.9%-7.8%58.1%40.3%

Price Volatility Vs. Market

How volatile is AgeX Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AgeX Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether AgeX Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AgeX Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of AGE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through AgeX Therapeutics regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is AgeX Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

30.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AgeX Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has AgeX Therapeutics performed over the past 5 years?

-8.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AGE is currently unprofitable.

Growing Profit Margin: AGE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGE is unprofitable, and losses have increased over the past 5 years at a rate of -8.4% per year.

Accelerating Growth: Unable to compare AGE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: AGE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is AgeX Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AGE has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AGE has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AGE has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AGE's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AGE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.6% each year


Next Steps

Dividend

What is AgeX Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Mike West (66yo)

3.42yrs

Tenure

US$1,041,701

Compensation

Dr. Michael D. West, also known as Mike, Ph.D., has been Chief Executive Officer of AgeX Therapeutics, Inc. since January 2017 and serves as its President. He is a Founder of AgeX Therapeutics, Inc. He has ...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD1.04M) is above average for companies of similar size in the US market ($USD594.10K).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michael West
Founder3.42yrsUS$1.04m0.065% $27.6k
Nafees Malik
Chief Operating Officer1.67yrsUS$518.99k0.42% $179.6k
Andrea Parks
Chief Financial Officer0.083yrno data0.00093% $395.7
Ivan Labat
Chief Information Officerno datano datano data
Judith Segall
Secretaryno datano data0.14% $59.5k

1.7yrs

Average Tenure

66yo

Average Age

Experienced Management: AGE's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael West
Founder3.42yrsUS$1.04m0.065% $27.6k
Gregory Bailey
Chairman of the Board1.67yrsUS$330.65kno data
Michael May
Independent Director0.83yrUS$36.51kno data
Annalisa Jenkins
Independent Director1.67yrsUS$310.67kno data

1.7yrs

Average Tenure

58.5yo

Average Age

Experienced Board: AGE's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AgeX Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AgeX Therapeutics, Inc.
  • Ticker: AGE
  • Exchange: AMEX
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$42.552m
  • Shares outstanding: 37.66m
  • Website: https://www.agexinc.com

Number of Employees


Location

  • AgeX Therapeutics, Inc.
  • 965 Atlantic Avenue
  • Suite 101
  • Alameda
  • California
  • 94501
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGEAMEX (NYSE MKT LLC)YesCommon SharesUSUSDNov 2018
0X4DB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2018

Biography

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company’s lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington’s disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/01 11:48
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.